CN1672688A - Medical composite chitinamine gel - Google Patents
Medical composite chitinamine gel Download PDFInfo
- Publication number
- CN1672688A CN1672688A CN 200410013639 CN200410013639A CN1672688A CN 1672688 A CN1672688 A CN 1672688A CN 200410013639 CN200410013639 CN 200410013639 CN 200410013639 A CN200410013639 A CN 200410013639A CN 1672688 A CN1672688 A CN 1672688A
- Authority
- CN
- China
- Prior art keywords
- chitinamine
- chitosan
- metronidazole
- sodium alginate
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The medicine composite chitinamine gel liquid consists of chitinamine 1-8 wt%, sodium alginate 2-12 wt% and metronidazole 0.1-0.6 wt% except distilled water. The medicine composite chitinamine gel liquid is prepared through mixing its components, and has the combined effects of flushing, sterilizing, diminishing inflammation, stopping bleeding, reducing scar and preventing adhesion. The present invention may be used widely in various kinds of surgical operation and is safe and no toxic side effect.
Description
(1), affiliated field
What the present invention relates to is the wild flushing liquor of a kind of medical operation art, the particularly a kind of wild flushing of art, antiblocking liquor that is suitable for clinical various operations.
(2), background technology
In the surgical procedures, comprise that the wild flushing of arts such as wound face processing of wound, burn and scald is necessary link and means, most of operation simultaneously need be done anti and handle, and all operation needs control wounded tissue inflammation and hemorrhage.At present, the wild flushing of the art in the clinical operation process still rests on based on normal saline, suitably adds on the antibiotic traditional method.Existing post-operation adhesion preventing goods exist dosage little (generally having only 3ml-5ml), can not guarantee to control the wild position tissue fluid of elimination art fully and ooze out the tissue adhesion that the injury cicatrization causes.With normal saline add an amount of antibiotic, the deficiency of using the traditional method of anti-blocking agent is mainly reflected in: the one, operation sequence will divide for three steps carried out, the art of not only performing the operation journey is long, and has increased the probability of postoperative infection.The 2nd, the anti-blocking agent ubiquity of using the defective of underdosage.The report that some flushing liquors are also arranged at present, but its effect is unsatisfactory, and also some compositions wherein have certain stimulation and toxicity to body tissue.
(3), summary of the invention
The object of the present invention is to provide a kind of medical compound chitosan gelatin liquid that integrates the wild flushing of art, anti-inflammation, hemostasis, minimizing cicatrization, prevention tissue adhesion.
The object of the present invention is achieved like this: it is that the water for injection of chitosan 1-8%, sodium alginate 2-12%, metronidazole 0.1-0.6% and surplus is formed by weight ratio.
After getting raw material ready in proportion, earlier metronidazole is dissolved in the water for injection, adds chitosan, sodium alginate more in succession, make product after mix homogeneously after-filtration, fill, lamp inspection, sterilization, the check.
Main component among the present invention is a chitosan, chitosan can be described as chitosan, chitosan, chitin, chitosan, chitin, chitin again, it is a kind of marine organisms macromolecular material, has nontoxic, good biocompatibility, has certain film property, viscosity, effectively characteristic such as pathogenic microbe killing.Another kind of composition sodium alginate among the present invention also is a kind of marine organisms macromolecular material, has and the akin characteristic of chitosan.Metronidazole is anti-amebic, antitrichomonal drug and antianaerobic-microbacterial drug, after effectively killing the art open country and closing, and the biological characteristicses such as pathogenic microorganism such as anaerobe that grow after particularly abdomen, pelvic cavity are closed.The present invention mixes chitosan with compositions such as sodium alginate, metronidazoles, the advantage of the medical compound chitosan gelatin liquid of composition is mainly reflected in: 1, can reach to operate in the wild flushing of art, the anti art and once finish, the art journey is shortened, reduce infection chance.2, the effect that has quick pathogenic microbe killing, especially anaerobe, the inflammatory that can reduce or eliminate wild position of art or anastomotic position changes.3, have hemostasis, inhibition tissue fluid inflammatory exudation, minimizing cicatrization, reach prevention tissue adhesion's purpose.4, applied range can be widely used in all types of operations of clinical each section.5, have good biology performance, can after the usefulness performance, be absorbed by the body.Have no side effect,, can not produce harmful effect user 6, safely.
(4), specific embodiments
For example the present invention is done in more detail below and describes:
1, by weight getting raw material ready for the water for injection of chitosan 1-8%, sodium alginate 2-12%, metronidazole 0.1-0.6% and surplus, earlier metronidazole is dissolved in the water for injection, adding chitosan, sodium alginate in succession, make product after mix homogeneously after-filtration, fill, lamp inspection, sterilization, the check.
2, by weight getting raw material ready for the water for injection of chitosan 2-5%, sodium alginate 4-9%, metronidazole 0.25-0.4% and surplus, earlier metronidazole is dissolved in the water for injection, adding chitosan, sodium alginate in succession, make product after mix homogeneously after-filtration, fill, lamp inspection, sterilization, the check.
3, by weight getting raw material ready for the water for injection of chitosan 3-8%, sodium alginate 5-12%, metronidazole 0.3-0.5% and surplus, earlier metronidazole is dissolved in the water for injection, adding chitosan, sodium alginate in succession, make product after mix homogeneously after-filtration, fill, lamp inspection, sterilization, the check.
4, by weight getting raw material ready for the water for injection of chitosan 4%, sodium alginate 8%, metronidazole 0.3% and surplus, earlier metronidazole is dissolved in the water for injection, adding chitosan, sodium alginate in succession, make product after mix homogeneously after-filtration, fill, lamp inspection, sterilization, the check.
Claims (2)
1, a kind of medical compound chitosan gelatin liquid is characterized in that: it is that the water for injection of chitosan 1-8%, sodium alginate 2-12%, metronidazole 0.1-0.6% and surplus is formed by weight ratio.
2, medical compound chitosan gelatin liquid according to claim 1 is characterized in that: it is that weight ratio is that the water for injection of chitosan 2-5%, sodium alginate 4-9%, metronidazole 0.25-0.4% and surplus is formed by weight ratio.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013639 CN1272019C (en) | 2004-03-24 | 2004-03-24 | Medical composite chitinamine gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013639 CN1272019C (en) | 2004-03-24 | 2004-03-24 | Medical composite chitinamine gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1672688A true CN1672688A (en) | 2005-09-28 |
| CN1272019C CN1272019C (en) | 2006-08-30 |
Family
ID=35045630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410013639 Expired - Fee Related CN1272019C (en) | 2004-03-24 | 2004-03-24 | Medical composite chitinamine gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1272019C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101360519B (en) * | 2006-01-16 | 2013-03-27 | 洛曼-劳舍尔国际股份有限公司 | Antiseptic alginate preparation |
| CN103203014A (en) * | 2013-03-06 | 2013-07-17 | 张巍 | Preparation method of blended functional surgical irrigating fluid |
| CN104173369A (en) * | 2013-05-22 | 2014-12-03 | 何佩峰 | Drug for burns |
| CN108653825A (en) * | 2018-06-09 | 2018-10-16 | 江苏海尔滋生物科技有限公司 | Cutting lavation fluid film and preparation method thereof |
-
2004
- 2004-03-24 CN CN 200410013639 patent/CN1272019C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101360519B (en) * | 2006-01-16 | 2013-03-27 | 洛曼-劳舍尔国际股份有限公司 | Antiseptic alginate preparation |
| CN103203014A (en) * | 2013-03-06 | 2013-07-17 | 张巍 | Preparation method of blended functional surgical irrigating fluid |
| CN104173369A (en) * | 2013-05-22 | 2014-12-03 | 何佩峰 | Drug for burns |
| CN108653825A (en) * | 2018-06-09 | 2018-10-16 | 江苏海尔滋生物科技有限公司 | Cutting lavation fluid film and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1272019C (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Massarelli et al. | Polyvinyl alcohol/chitosan wound dressings loaded with antiseptics | |
| CN106068133B (en) | Method for preparing wound dressing using biopolymer, and wound dressing using biopolymer prepared by the method | |
| EP2121048B1 (en) | Hemostatic compositions and therapeutic regimens | |
| EP1796752B1 (en) | Biomaterials consisting of sulphated hyaluronic acid and gellan to be used in the prevention of spinal adhesions | |
| CA2312558C (en) | Collagen containing tissue adhesive | |
| EP3060266B1 (en) | Chitosan paste wound dressing | |
| CA2409076A1 (en) | Composition and method for growing, protecting, and healing tissues and cells | |
| US7387785B1 (en) | Preparation for treating diseases of bone tissues | |
| CN109432481A (en) | A kind of polyurethane dressing of hemostatic and antibacterial and preparation method thereof | |
| CN115124738B (en) | Double-layer bionic drug-loaded hydrogel and preparation and application thereof | |
| CN101011606A (en) | Anti-sticking flush fluid | |
| CN107899003A (en) | A kind of chitosan oligomer medical wound nursing film and preparation method thereof | |
| CN105477679B (en) | Based on the crosslinked chitosan quick-acting haemostatic powder cotton of polysaccharide | |
| CN1272019C (en) | Medical composite chitinamine gel | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| CN110478349B (en) | Dressing for wound care and preparation method thereof | |
| JP6725108B2 (en) | Disinfecting composition containing unithiol and dimethyl sulfoxide, use of the composition and method for treating wound using the same | |
| AU740832B2 (en) | Dextrin-containing composition for preventing surgical adhesions | |
| Li et al. | Effect of “phase change” complex on postoperative adhesion prevention | |
| US20200023042A1 (en) | Composition for wound healing | |
| CN105126154B (en) | A kind of medical bio nasal cavity rapid hemostasis powder and preparation method thereof | |
| WO2017060821A1 (en) | Hemostatic composition | |
| CN1037818C (en) | Method for preparing medical biologic film | |
| CN114984132B (en) | Wound spray capable of promoting coagulation and repair and preparation method thereof | |
| CN113230205B (en) | Gynecological gel preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |